Hepatitis C News

Researchers determined a target limit of detection for hepatitis C point-of-care tests that would identify 97% of viremic infections among all populations including low- and middle-income countries, according to a recently published study.

Results of a prospective study showed that treatment with direct-acting antivirals for hepatitis C correlated with significantly reduced risks for hepatocellular carcinoma and mortality, according to a study published in The Lancet.

As researchers continue to focus on hard-to-reach populations for hepatitis C testing and treatment, the ongoing opioid epidemic presents an opportunity for prevention as treatment through outreach and education in the regions with highest injection drug use.

More than two-thirds of patients with hepatitis C who visited a Federally Qualified Health Center in Philadelphia were linked to care, including both antibody and RNA testing, and many continued to medical evaluation, according to a study published in Hepatology.

Among the three largest Hispanic population subgroups, researchers found high levels of heterogeneity in chronic liver disease-related mortality patterns, according to a recently published study.

Patients undergoing direct-acting antiviral therapy for hepatitis C who had non-characterized liver nodules had a higher risk for hepatocellular carcinoma within a short follow-up time than other patients, according to a recently published study.

Lincoln Financial Group and the American Liver Foundation have joined together to raise awareness of hepatitis C in the U.S. and improve educational resources, according to a press release.

Between 2010 and 2017, the number and percentage of deceased donor organs with a transmissible infectious disease — such as hepatitis C, hepatitis B or HIV — increased in the U.S., which may likely be tied to the ongoing opioid epidemic, according to a recent report from the CDC.

Patients with complete response to hepatocellular carcinoma and underwent direct-acting antiviral therapy for hepatitis C had similar rates of cancer recurrence compared with patients who did not receive DAA therapy, according to a study published in Gastroenterology.

HepVu — an interactive online resource designed to visualize data on the U.S. hepatitis C epidemic — announced the release of new interactive maps that provide state-level estimates of HCV infections, according to a press release and online presentation.